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ABSTRACT
This thesis consists of molecular genetic studies on Finnish families with a dominantly
inherited predisposition to colorectal cancer. The more prevalent disease, hereditary
nonpolyposis colorectal cancer (HNPCC) is caused by a defect in mismatch repair – an
evolutionary conserved molecular mechanism responsible for correction of DNA
replication errors. In addition to colorectal cancer, endometrial, gastric, pancreatic,
small intestinal and uroepithelial cancers are encountered in excess among HNPCC
patients compared with the general population.
Fifty-five Finnish HNPCC families were screened for MLH1 and MSH2 mutations.
Two common founder mutations in MLH1 were found to account for the major part of
mutation-positive families. One of these is a large genomic deletion of 3.5 kb that leads
to an in-frame deletion of exon 16 (“Mutation 1”), and the other is a splice site
nucleotide change that leads to an out-of-frame deletion of exon 6 (“Mutation 2”). We
showed that all HNPCC patients from the families harboring either one of these
mutations share a common ancestral haplotype. The observed recombinations flanking
the MLH1 gene allowed us to calculate that the expansion of mutations 1 and 2 in the
Finnish population started approximately 16-43 generations and 5-21 generations ago,
respectively. These estimates were compatible with the previous genealogical data
identifying a common ancestor born in the 16
th and 18
th century, respectively.
The common ancestral origin of the predisposing HNPCC mutations was used as an
interesting basis for the association analysis of three polymorphic genes (NAT1, GSTM1
and GSTT1) coding for carcinogen metabolizing enzymes with putative low-penetrance
colon cancer risk alleles. The rapid acetylator allele NAT1*10 was associated with distal
colon tumor location and with somewhat lower age at diagnosis in the large group of
HNPCC patients with mutation 1.
The molecular genetic basis of the tumor spectrum in HNPCC is not well understood.
To approach this problem, we compared the immunohistochemical staining patterns of
three major mismatch repair proteins (MLH1, MSH2, and MSH6) in colorectal cancers
and endometrial cancers from patients with MLH1 or MSH2 germline predisposition.
As expected from the “two-hit” hypothesis, the MLH1 protein was not expressed in
tumors from MLH1 germline mutation carriers. Interestingly, the MSH2 and/or MSH6
proteins were not expressed in about 50% of the endometrial cancers, but were present
in all the colorectal cancers from MLH1  mutation carriers. We conclude that the
MSH2/MSH6 protein complex plays an essential role in the pathogenesis of
endometrial cancer compared with colorectal cancer in HNPCC.
The other syndrome predisposing to a high risk for hereditary colorectal cancer, familial
adenomatous polyposis (FAP), is caused by a germline mutation in the large
adenomatous polyposis coli (APC) gene located in the chromosome band 5q21. We
studied 65 Finnish FAP families to characterize the predisposing APC mutations, to
address the possible founder effect, and to conduct genotype-phenotype correlations.
Thirty-eight different truncating mutations were identified in 47 families with no
evidence of a founder effect. This study has laid the ground for the molecular genetic
testing of FAP in Finland, and forms a basis for further molecular studies.9
REVIEW OF THE LITERATURE
1. CANCER AS A DISEASE
The knowledge, diagnostics, treatments, and prognosis of cancer have improved
tremendously during the past decades. Basically, cancer is a disease of genes that
control the proliferation, differentiation, and death of our cells. Most cancers are
derived from single somatic cells and their progeny as a result of favored selection for
mutated clones. The features that characterize malignant cells are self-sufficiency in
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of
programmed cell death (apoptosis), limitless replication potential, sustained
angiogenesis, tissue invasion and metastasis (Hanahan and Weinberg 2000).
1.1. Cell cycle and apoptosis
Homeostasis within a cell population or tissue is a balanced state between cell
proliferation and cell death. If this balance is disturbed and the rate of cell proliferation
exceeds that of cell death, growing tissue proceeds to form what slowly develops into a
tumor.
The fundament of the cell cycle is to ensure that the genetic material (i.e. the DNA
packed in chromosomes) is faithfully replicated and passed to the next generation of
cells. The cell cycle consists of four coordinated phases. Chromosomes replicate during
the S(ynthesis) phase. During M(itosis), cellular microtubules form a spindle structure
that separates the replicated chromosomes and the nucleus divides. Two G(ap) phases
(G1 and G2) intervene between the S and M phases, allowing time for cellular growth
and differentiation. Cells in different tissues cycle at different rates: the epithelial cells
of the colon or endometrium are in a constantly dividing state, whereas liver cells or
fibroblasts are in a non-dividing state (G0), but can re-enter the G1 phase, for example
in response to tissue damage (Clurman and Roberts 1998).
If the cellular genome is somehow injured, the cycling cell can be arrested at G1, S, G2
or M checkpoints to allow repair. DNA damage caused by X-rays, oxygen radicals,
alkylating agents, UV light, polycyclic aromatic hydrocarbons, anti-tumor agents,
spontaneous chemical reactivity or replication errors are sensed and corrected by
various nuclear repair mechanisms (Hoeijmakers 2001). If the DNA repair mechanisms
fail, the cell may be triggered to apoptosis, a controlled process of cell death during
which the cell shrinks, the nucleus is condensed and cellular DNA is autodigested.
Apoptosis does not induce inflammatory response. Cancer cells, and most apparently
metastatic cells, do not response adequately to these physiologic tissue specific stimuli,
because their ability to undergo apoptosis is lost (Thompson 1995).10
1.2. Oncogenes and tumor suppressor genes
Oncogenes were first identified as transforming genes in viruses that, when transferred
to non-neoplastic cells, "transformed" them into cells behaving malignantly. Their
normal human counterparts, called proto-oncogenes, usually control the strategic steps
of normal cell growth and differentiation. Gain-of-function events, such as activating
mutation, chromosomal rearrangement, or gene amplification, may turn proto-
oncogenes into oncogenes that enhance cell proliferation, or render the cells immortal
because they evade apoptosis (Park 1998). At the present state of the Human Genome
Project, over 100 dominant oncogenes are known (Futreal et al 2001). Most activating
changes are somatic events. However, some rare familial cancers are caused by
constitutive mutations in oncogenes (Mulligan et al 1993, Nishida et al 1998).
Knudson formulated his "two-hit hypothesis" to explain the age distribution of inherited
and sporadic retinoblastomata (Knudson 1971). The RB1 gene, which was cloned using
somatic deletions in chromosome 13 as signposts, is a prototype of this gene class
(Weinberg 1991). Tumor suppressors are recessive genes, i.e. loss of function results
from inactivation of both alleles within a single cell. Inactivation results from germline
or somatic mutation, loss of heterozygosity (LOH), or epigenetic silencing. Many of the
30 known tumor suppressors have been identified using positional cloning in inherited
cancer syndromes (Fearon 1998, Futreal et al 2001).
The heterogeneous group of tumor suppressor genes has been subclassified into
gatekeepers, caretakers, and landscapers (Kinzler and Vogelstein 1997, 1998). Biallelic
inactivation of gatekeepers or "classical" tumor suppressors, such as p53, RB1, VHL, or
APC, is rate-limiting for cancer development and is usually tissue-specific. Loss of a
caretaker gene function is not essential for cancer development, but accelerates the
course of other events in the pathogenesis. Caretakers are thus indirect suppressors. The
genes involved in various DNA repair systems and cell cycle control mechanisms
belong to this group (Kinzler and Vogelstein 1997). The "landscaper hypothesis" was
postulated to explain conditions such as endometrial polyps, ulcerative colitis, or
hamartomatous juvenile polyposis, where clonal alterations are detected in stromal, but
not in epithelial, cells (Kinzler and Vogelstein 1998). The stromal microenvironment is
known to modify the proliferative and invasive behavior of many tumors (Liotta and
Kohn 2001).
1.3. Epigenetic mechanisms
Epigenetic regulation of gene expression by methylation, such as imprinting (silencing
of either one of the parental alleles or chromosomal areas) and lyonization (silencing
one of the X-chromosomes in female mammals), determines cell fate during
embryogenesis.
Epigenetic modifications of cancer genes, passed to subsequent clonal cell generations,
are important in carcinogenesis. Global hypomethylation (Feinberg et al 1988) and CpG
hypermethylation at promoter regions (Herman et al 1995, Hiltunen et al 1997) have
been reported. Loss of imprinting (LOI) with subsequent over-expression of insulin-like
growth factor (IGF) 2 has been observed in many tumors, including those of the large
bowel (Rainier et al 1993, Cui et al 1998).11
Cytosine residues at CpG sites are targets for methylation. Deamination of the
methylated cytosine residues results in C>T changes, mismatches, and point mutations.
Somatic methylation of normally unmethylated "CpG islands", located near promoters
of many mammalian genes, causes transcriptional silencing and reduced protein
expression of respective genes. Aging is one major contributor to the increased level of
CpG island methylation in colonic mucosa (Ahuja et al 1998).
In a subgroup of colorectal adenomas and cancers, the CpG island methylation is
present independently from the age-dependent methylation of the normal colon. This
phenomenon is called the CpG island methylator phenotype (CIMP) (Toyota et al
1999). Several known tumor suppressor genes, like p16, THBS1, TIMP3, and MLH1,
are inactivated by promoter hypermethylation in CIMP+ tumors (Toyota et al 2000).
Analyses of the mutational events in K-ras, p53, DPC4 and TGFβ R2 genes indicate that
the CIMP status represents a distinct molecular pathogenic etiology leading to
colorectal cancer (Toyota et al 2000).
2. COLON CANCER
Colorectal cancer is common worldwide, and its macroscopic and histologic
development from benign precursor lesions has been well described. The organ is
accessed by endoscopy, and tissue material for diagnostic as well as research purposes
can be obtained relatively easily. Analyses of FAP- and HNPCC -related tumors have
helped to understand many details of the molecular pathogenesis in general.
2.1. Epidemiology and pathology
Over 2000 cases of colorectal cancer are diagnosed in Finland each year, the mean age
at diagnosis being 70 years (Finnish Cancer Registry 1997). From epidemiologic
studies it is known that a high-fat-low-fiber diet, high consumption of red meat, or a
long history of smoking are associated with an increased risk of colorectal cancer. In
contrast, a diet rich in fruit and vegetables and the use of estrogen replacement therapy
or non-steroidal anti-inflammatory drugs (NSAIDs) seem to reduce the risk (Potter
1999). Early detection and removal of premalignant lesions significantly reduce the
mortality from colorectal cancer, emphasizing the importance of well-targeted
screening protocols (Burt 2000).
All colon epithelial cells in one crypt are derived from 4-6 stem cells located in the
bottom of each crypt. The cells gradually differentiate into enterocytes, migrate
upwards, and eventually die or are shed from luminal epithelial surface. If one stem cell
acquires a mutation resulting in selection advantage, about a year of competition
elapses before all the stem cells in the crypt carry the same mutation. The process from
an early dysplastic lesion to metastasizing cancer is slow (10-15 years on average),12
although in practice the time interval is determined by genetic constitution,
accumulation of environmental risk factors, and chance (Vogelstein and Kinzler 1993)
Macroscopically a colon tumor first arises as a small benign hyperplastic lesion that
progress to an exophytic benign polyp, and through advancing adenomatous growth
eventually to a malignant metastasizing cancer. All premalignant lesions do not have
the round polypotic appearance. Flat and centrally depressed adenomas, serrated
adenomas, and large hyperplastic polyps are distinct groups of tumors with malignant
potential, but follow different molecular pathogenetic events (Rashid et al 2000,
Watanabe and Muto 2000).
The majority of colon tumors are located in the distal third of the colorectum.
Embryologically, the proximal part from the caecum to the splenic flexure originates
from the hindgut, and the distal part from the midgut. It has been postulated that
different genes are involved in the pathogenesis of proximal and distal colon tumors
(Bufill JA 1990). In addition, different luminal microenvironments may modulate gene
expression along the digestive tract (Glinghammar and Rafter 2001). Interesting links
between colon tumor localization, the environmental carcinogen load, and the various
types of genetic alterations have been recently discussed (Lindblom 2001).
2.2. Colon cancer and heredity
Some type of genetic predisposition accounts for 10-30% of all colorectal cancers.
First-degree relatives of patients with colon cancer consistently have a 2- to 3-fold
increased risk for the same disease, whereas spouses do not (Burt 2000). Most familial
risk is probably attributable to several inherited, low penetrance genes in combination
with environmental risk factors, such as dietary carcinogens.
Less than 5% of all colorectal cancers are associated with dominant inheritance.
HNPCC is estimated to account for approximately 2-3% of colorectal cancers. Exact
figures are difficult to determine, however, since the tumors lack specific macroscopic
hallmarks, the penetrance of germline mutations is about 80%, and 30-40% of clinically
verified cases of HNPCC fail to show any predisposing mutations (Lynch and de la
Chapelle 1999). Epidemiologic studies based on nation-wide registers indicate that the
prevalence of FAP is 26-32x10
-6, and the proportion of FAP is 0.1% of all colorectal
cancers (Järvinen 1992, Bülow et al 1996). The penetrance rate of the underlying
germline mutation is near 100% by the age of 40. About 20% of the cases are caused by
de novo mutations (Bisgaard et al 1994).
Less than 0.1% of all colorectal cancers are associated with rare hamartomatous
polyposis syndromes. Peutz-Jeghers syndrome is caused by a mutation in the STK11/
LKB1 gene (Hemminki et al 1998), juvenile polyposis by a SMAD4/DPC4 mutation
(Howe et al 1998), and Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome
by germline mutations in the PTEN/MMAC gene (Marsh et al 1998).
Discovering the genetic background of rare Mendelian syndromes has led to new fields
of research. However, most of the genetic cancer risk at population level is attributed to
genes (or alleles) with moderate or low penetrance. Because such genes may have only
a small net effect on genetic fitness, they are not strongly selected against, allowing15
methyl-N’-nitro-N-nitrosoguanine (MNNG) exhibit microsatellite instability (MIN).
Vice versa, cells rendered on purpose into CIN cells, or cells with naturally occurring
MIN, were resistant to the respective drugs (Bardelli et al 2001).
2.4.1. Chromosomal instability
The majority (75-85%) of all colorectal cancers shows gains or losses of gross
chromosome material as a result of aberrant mitotic recombination or chromosome
segregation (Kinzler and Vogelstein 1996).
Aneuploidy refers to changes in the number of chromosomes that result from gains or
losses of whole chromosomes. Chromosomal breaks and rearrangements can be
analyzed by karyotyping or by fluorescence in situ hybridization (FISH) techniques.
Translocations may give rise to new fusion genes, or the regulatory control of a gene
may be interfered with. Both situations may convert proto-oncogenes to oncogenes.
Very small losses of chromosomal material may be detectable only with molecular
hybridization methods (FISH) or PCR-based analysis using regional microsatellite
markers (LOH). Gene amplifications increase the copy number of DNA sequences and
may lead to overexpression of one or several of the genes within the amplicon (Heim
and Mitelman 1995).
CIN is transferred as a dominant trait in colon cancer cells (Lengauer et al 1997a). It is
typical of distal colorectal cancers and is associated with DNA hypomethylation
(Lengauer et al 1997b). In detailed analyses, 95% of colon tumors from FAP patients
exhibit molecular changes of CIN-type (Konishi et al 1996). The molecular mechanism
that causes CIN is not precisely known (Lengauer et al 1998), but defects in the mitotic
spindle checkpoint due to the lost BUB1 gene have been implicated (Cahill et al 1998).
Accumulation of chromosomal aberrations in mouse embryonic stem cells homozygous
for the truncating Apc mutation downstream of the β -catenin binding region suggests a
role for Apc-EB1 binding (Fodde et al 2001).
2.4.2. Microsatellite instability
Of the sporadic colorectal cancers, 10-15% are diploid, or near diploid, and show
chromosomal aberrations or LOH at 17p, 18q, or 5q only infrequently (Konishi et al
1996). Instead, when compared with the patient’s constitutional genotype, multiple
minor sequence changes are present in the tumor DNA, and seen as novel alleles at
microsatellite loci (Aaltonen et al 1993).
Microsatellites are short, repetitive (with repeat units of 1-6 bp) DNA tracts widely
scattered throughout the genome. They may occur as part of both coding and non-
coding regions. They are prone to "slippage" of the polymerase machinery during
replication, resulting in conformational mismatches and small loops corrected mainly
by the postreplication mismatch repair (MMR) mechanism (Jiricny 1998). If the MMR
fails, new alleles are formed at microsatellite loci and replicated as an integral part of
the clonal genome in successive cell cycles. The nomenclature for the phenomenon,
microsatellite instability, is variable, and the terms RER (replication error) or MIN/MSI
(microsatellite instability) are in use.16
Many genes have short coding repeats that are targets for somatic frameshift mutations
in MMR-compromised cells. Mutations in the (A)10 tract of the TGFβ R2 gene are found
in 90% of MIN colorectal tumors (Markowitz et al 1995). Similar changes have been
identified in IGF2R (Souza et al 1996), PTEN (Tashiro et al 1997), transcription factors
E2F4 and TCF4 (Souza et al 1997, Duval et al 1999a), apoptosis-related genes BAX and
caspase-5 (Rampino et al 1997, Schwartz 1999), MSH3, MSH6, and MBD4 related to
mismatch repair (Yamamoto et al 1997, Riccio et al 1999), AXIN2 and WISP3 involved
in WNT signaling (Liu et al 2000, Thorstensen 2001), and the homeobox gene CDX2
(Wicking et al 1998).
To overcome problems that arise from the use of different microsatellite marker panels,
a “standard panel” of five markers (BAT25, BAT26, D5S346, D2S123, and D17S250)
was recommended (Boland et al 1998). The quasimonomorphic BAT26 located in IVS5
of the MSH2 gene is the most sensitive marker for detecting highly unstable tumors
(Hoang et al 1997, Dietmaier et al 1997, Aaltonen et al 1998). Tumors unstable for two
or more of the five recommended markers (>30% of the markers in a panel) are
classified as MSI-H(igh), while tumors unstable for only one marker (< 30%) are
classified as MSI-L(ow). The molecular genetic changes in tumors with no instability
(MSS) roughly correspond to those of the CIN tumors (Konishi et al 1996, Jass et al
1999).
MSI-H tumors are more often located in the proximal than in the distal colon. Mucinous
and poorly differentiated adenocarcinomas are over-represented (Kim et al 1994,
Shashidharan et al 1999). The enhanced lymphocyte response ("Crohn-like reaction")
and the low tendency to emit liver metastases probably account for the somewhat better
prognosis of MSI+ colon cancers, as reported in several studies (Lothe et al 1993,
Sankila et al 1996, Watson et al 1998). MSI+ colon cancers in young patients are
associated with germline mutations in MLH1 or MSH2 (Liu et al 1995, Farrington et al
1998), whereas sporadic MSI+ tumors diagnosed at old age are associated with
epigenetic silencing of the MLH1 promoter, an important target in CIMP as well (Veigl
et al 1998, Toyota et al 1999).
In addition to colon cancers, 10-20% of endometrial and gastric cancers show MSI.
Different coding-repeat mutation profiles in MSI+ tumors derived from different organs
may reflect tissue-specific pathogenic routes (Myeroff et al 1995, Kong et al 1997,
Duval et al 1999b).
2.5. Molecular epidemiology and colon cancer modifier genes
Low penetrance genes that contribute to multifactorial diseases or complex traits are
difficult to pinpoint with traditional linkage methods. Most suggestions have come from
association studies that compare the frequencies of candidate risk alleles between cases
and controls. Polymorphic variants of genes that code for carcinogen metabolism
enzymes, methylation enzymes, DNA repair proteins, microenvironmental modifiers,
tumor suppressors or oncogenes have been studied as possible low penetrance colon
cancer genes (Houlston and Tomlinson 2001).
The concept of a “modifier gene” derives from the observation that a single locus
(named Mom1, or Modifier of Min 1) in mouse chromosome 4 modifies the number of17
intestinal polyps in Min mice (Dietrich et al 1993). The underlying gene, phospholipase
a2 (Pla2g2a), was thought to act by altering the cellular microenvironment, possibly
through prostaglandin synthesis (MacPhee et al 1995). Cyclooxygenase-2 (COX-2) is
an inducible enzyme needed for the conversion of arachidonic acid into prostaglandins.
In intestinal cancers it is overexpressed. NSAIDs reduce the size of adenomas and
polyps both in mice and in humans, an effect mediated by COX-2 inhibition
(Taketo1998a, 1998b). The human locus 1p35-36, which is syntenic with Mom1, has
been suggested to modify the severity of duodenal polyposis and extracolonic
manifestations in FAP (Tomlinson et al 1996, Dobbie et al 1997). However, in
attenuated adenomatous polyposis patients, no association has been confirmed between
variant alleles of either PLA2G2A or COX-2 and the number of polyps (Spirio et al
1996, Spirio et al 1998).
N-acetyltransferases 1 and 2 (NAT1 and NAT2) are phase II enzymes that detoxify a
number of dietary aromatic and heterocyclic amine carcinogens derived especially from
well-cooked red meat. Both genes are highly polymorphic, with functionally ”slow”
and “rapid” alleles (Hein et al 2000). A nearly two-fold increased risk of colon cancer
associated with the “rapid” allele NAT1*10  has been reported (Bell et al 1995a),
although other investigators have not confirmed the finding (Chen et al 1998).
Other genes, reported to present with alleles that may increase the risk for colon cancer,
code for the phase I detoxifying enzyme CYP1A1, the phase II metabolizing enzymes
glutathione-S-transferases M1 and T1 (GSTM1 and GSTT1), and the 5,10-
methylenetetrahydropholate (MTHFR) involved in folate metabolism and thus possibly
influencing DNA methylation (Houlston and Tomlinson 2001).
3. HEREDITARY NON-POLYPOSIS COLORECTAL CANCER
(HNPCC)
Approximately 1-5% of all colorectal cancers in Western countries relate to HNPCC
(OMIM 120435 and 120436). The cancer risk among mutation carriers, analogous to
the penetrance rate of the underlying gene defect, is 80% by the age of 70 years. The
mean age at colon cancer diagnosis is 45 years, i.e. significantly younger than for
sporadic colon cancers. Gastric, ovarian, small bowel, pancreas, biliary tract and
uroepithelial cancers are more common in HNPCC than in the general population,
whereas breast, lung, or prostate cancers are not overrepresented (Lynch and Smyrk
1996, Vasen et al 1996).
HNPCC is caused by an inherited mutation in one of the DNA mismatch repair genes
MLH1, MSH2, MSH6, PMS2 or PMS1 (Fishel et al 1993, Leach et al 1993, Bronner et
al 1994, Papadopoulos et al 1994, Nicolaides et al 1994, Miyaki et al 1997). Over 300
predisposing mutations are known and recorded in electronic databases (Peltomäki et al
1997, http://www.nfdht.nl, http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html). Only one
PMS1 mutation was reported in the early literature (Nicolaides et al 1994).18
MLH3 and MSH3 proteins participate in the mismatch repair protein complex (Lipkin
et al 1999, Edelmann et al 2000), but their significance as genes predisposing to
HNPCC is still a matter of controversy (Wu et al 2000, Huang et al 2001). The
exonuclease 1 (EXO1) protein interacts with MSH2 (Tishkoff et al 1998), and germline
variants of the respective gene were recently identified in several atypical HNPCC
families (Wu et al 2001).
3.1. Clinical criteria of HNPCC
Though the cancer family syndrome has been known since the beginning of the last
century, the clinical diagnostic criteria of HNPCC were determined only in 1991 by an
international consortium (Vasen et al 1991). According to these “Amsterdam criteria”
(AC), HNPCC is diagnosed when 1) there are at least three colorectal cancer patients in
at least two successive generations in the family, 2) at least one cancer patient is a first
degree relative of the other two, 3) at least one case of cancer has been diagnosed in a
patient under the age of 50, and 4) familial adenomatous polyposis is excluded.
These criteria (referred to as AC I) turned out to be too strict. Small families, families
with endometrial rather than colon cancer cases, or families with a later age at diagnosis
do not fulfill ACI, although germline mismatch repair gene mutation may be present.
The less strict “Bethesda guidelines” were proposed as the basis for molecular
screening of putative HNPCC (Rodriguez-Bigas et al 1997), and new diagnostic criteria
(ACII), which take into account endometrial, small bowel, ureteral and renal pelvis
cancers, were formulated (Vasen et al 1999).
3.2. Tumor spectrum in HNPCC
3.2.1. Colon cancer
Roughly two-thirds of all cancers in HNPCC families are colorectal. The lifetime risk is
higher in males (74%) than in females (30%), and metachronous and/or synchronous
cancers occur in 30% of patients (Dunlop et al 1997, Vasen et al 1996). Two-thirds are
located in the proximal colon, and ≈ 90% are MSI-H with typical histologic features. If
the predisposing mutation in the family is not known, immunohistochemical staining of
tumor tissue to observe the lack of nuclear expression of MLH1, MSH2, or MSH6
protein can be used to target mutation analyses (Thibodeau et al 1996, Terdiman et al
2001).
3.2.2. Endometrial cancer
Familial aggregation of endometrial cancer, alone or in conjunction with colon cancer,
has been shown in both pedigree and population-based studies (Sandles et al 1992,
Gruber and Thompson 1996, Pal et al 1998, Hemminki et al 1999). Part of this familial
accumulation may represent atypical HNPCC (Cohn et al 2000). Endometrial cancers
are classified in two histological subtypes. Type I or endometrioid carcinoma is
“estrogen-related” and, analogously to the adenoma-carcinoma sequence, its
pathogenesis is a continuum from a proliferating endometrium via hyperplasia to
invasive carcinoma. Type I cancers are often well differentiated, and have a relatively
good prognosis. Type II or serous carcinomas account for 10-20% of all endometrial19
cancers. The pathogenesis of type II is unrelated to estrogen stimulation and the tumors
behave more aggressively. Somatic mutations in the PTEN tumor suppressor and K-ras
oncogenes are typical for type I, whereas accumulation of p53 protein characterizes
type II cancers (Sherman 2000).
Surprisingly little is known about the pathogenic molecular events in endometrial
tumorigenesis as compared with colon cancer. Of all endometrial cancers, 10-20% are
MSI+ (Peltomäki et al 1993a, Risinger et al 1993), mostly due to MLH1 promoter
hypermethylation in non-HNPCC cases (Gurin et al 1999). The lifetime risk of
endometrial cancer among female carriers of the HNPCC mutation varies between 22
and 60% (Watson et al 1994, Aarnio et al 1999, Dunlop et al 1997) and inactivation of
the MSH2-MSH6 complex seems to be an important factor (de Leeuw 2000, Schweizer
et al 2001). In endometrial MSI-positive cancers, mononucleotide tracts of PTEN and
IGF2R, rather than TGFβ R2, are targeted (Ouyang et al 1997, Duval et al 1999b,
Bussaglia et al 2000, Kuismanen et al, manuscript submitted).
3.2.3. Other HNPCC-related cancers
Gastric cancer is the third most common cancer in HNPCC families (Watson and Lynch
1993, Park et al 1999), and overrepresentation of the intestinal subtype has been
reported (Aarnio et al 1997). In HNPCC, the relative risk of ovarian, small bowel,
biliary tract, and uroepithelial cancers is increased, the mean age at diagnosis being 10-
20 years younger than in the general population (Watson and Lynch 1993, Lynch and
Smyrk 1996).
Coincidence of at least one sebaceous skin tumor (sebaceous adenoma, epithelioma,
keratoacanthoma, sebaceous carcinoma) and internal malignancy is called Muir-Torre
syndrome (OMIM 158320). In half of the cases, the internal malignancy is colorectal
cancer. Approximately 15% of female Muir-Torre patients have endometrial cancer
(Cohen et al 1991). Germline mutations in MSH2 and MLH1 have been identified in
Muir-Torre patients (Kruse et al 1998), and their skin tumors exhibit a high degree of
MSI.
Association between colon and brain tumors is called Turcot’s syndrome (OMIM
279300), although molecular studies have revealed two different entities. In two-thirds
of the cases with a dominant inheritance pattern, the brain tumors are derived from
neuronal cells (medulloblastomas) and are associated with APC germline mutations. In
one third of cases, the brain tumors derive from supportive glial cells (glioblastomas)
and associate with MLH1 or PMS2 germline mutations (Hamilton et al 1995). Recently,
a patient was reported with two different missense mutations in PMS2 inherited from
healthy parents (De Rosa et al 2000), suggesting a recessive mode of inheritance.
3.3. Molecular genetic background of HNPCC
3.3.1. Mismatch repair mechanism
The mismatch repair mechanism has been highly conserved during evolution, being
found in all species from unicellular bacteria to mammals. The illustration of the
mismatch repair process in mammalian cells is illustrated in Figure 3 (p. 20). A
mismatch in the DNA strand is recognized by a MutS heterodimer. The MSH2-MSH621
genome to recover from the helix-distorting lesions caused by UV light (Mellon et al
1996). Exposure to the alkylating agent MNNG, resulting to helical mismatches, causes
G2 cell cycle arrest in MMR proficient cells (Hawn et al 1995). In contrast, MMR
compromised cells show resistance to such alkylating agents (Branch et al 1995),
assumed to result from “futile cycles” of repair. These in vitro observations may have
clinical implications when cytotoxic drugs are used in the treatment of HNPCC
patients.
3.3.2. Genotype-phenotype correlations in HNPCC
The interacting MLH1 and MSH2 protein regions are known to some extent (Pang et al
1997, Guerrette et al 1998, Guerrette et al 1999, Ban et al 1999) but, in contrast to FAP,
mutations in particular regions do not correlate with specific clinical phenotypes. Most
of the reported HNPCC mutations are nonsense mutations, small deletions/insertions, or
single nucleotide splice site changes. Over 85% of MSH2 mutations belong to these
groups, whereas ≈ 30% of reported MLH1 mutations are missense mutations
(http://www.nfdht.nl). The latter should be distinguished from non-functional
polymorphisms, preferentially by using a functional test. Patients with compound
heterozygous MLH1 missense germline mutations have been reported to present the
constitutional mutator phenotype (Hackman et al 1997, Wang et al 1999), whereas
some heterozygous germline missense mutation carriers develop MSI-negative colon
tumors (Liu et al 1999, Genuardi et al 1999).
HNPCC families were previously classified as Lynch I and Lynch II syndromes,
according to the absence or presence of extracolonic manifestations (Lynch et al 1993).
However, there seems to be no molecular support for this classification, although
extracolonic tumors are more common in families with MSH2 mutations than in those
with the MLH1 mutations (Vasen et al 1996, Peltomäki et al 2001). Five Danish
families with an MLH1 intron 14 splice donor mutation that leads to a silenced allele
have remarkably few extracolonic cancers. The lack of a dominant negative effect is
postulated as the molecular mechanism for this “milder” phenotype (Jäger et al 1997).
The MSI-H tumor phenotype mainly involving di- and trinucleotide repeats is
associated with MLH1 or MSH2 mutations (Bapat et al 1999), whereas the tumors in
MSH6 mutation carriers are MSI-L and are unstable predominantly in mononucleotide
repeats (Wu et al 1999, Parc et al 2000). MSH6 germline mutations are often associated
with atypical HNPCC with more advanced age at diagnosis, and high frequency of
endometrial cancers (Wijnen et al 1999, Wagner et al 2001). The MSH6 gene has a (C)8
tract in its coding sequence, a natural target for a "second hit" (Wijnen et al 1999).
Brain cancer is not considered to be an integral part of HNPCC, although part of
Turcot’s syndrome is related to MMR gene mutations (see 3.2.3.). Among Finnish
HNPCC families, brain tumors affect only a few of the families sharing one of the
Finnish founder mutations (Peltomäki et al 2001). This observation may suggest co-
segregation of some brain-specific low penetrance gene in these families. Single
families with hematologic malignancy, neurofibromatosis 1, and histiocytoma
associated with HNPCC have been reported (Ricciardone et al 1999, Wang et al 1999,
Sijmons et al 2000).22
4. FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
The first description of massive adenomatous colon polyposis dates back to the year
1859, and its familial nature was described in 1882 (Phillips et al 1994). The
association between polyposis, osteomas, epidermoid cysts, and fibromas (“Gardner’s
syndrome”) was considered to be an independent entity (Gardner and Richards 1953),
but later was shown to be an allelic variant of the classical FAP (OMIM 175100).
Actually, the majority of FAP patients develop some extracolonic manifestations of the
disease.
4.1. Tumor spectrum in FAP
4.1.1. Colorectal polyposis
The diagnostic hallmark of classical FAP is the presence of >100 polyps in the colon
and/or rectum in the teens or in early adulthood. Polyposis as such is a premalignant
disease. However, some of the polyps will inevitably proceed to the adenoma-
carcinoma sequence, resulting in cancer by the age of 40-45 years. The age range of
cancer is from late childhood to the seventh decade. To prevent malignancy, endoscopic
diagnosis of familial polyposis always involves prophylactic colectomy (Phillips et al
1994).
Some patients and/or families present with a milder or more variable form of colorectal
polyposis called attenuated adenomatous polyposis (AAPC). In these patients, the
number of polyps varies from a few to more than 100 and they develop at a later age
(Spirio et al 1993). However, the risk of malignancy is not significally reduced as
compared with classical FAP. In AAPC families, the truncating mutations reside in
specific regions of the APC gene (see Figure 4, p. 24).
4.1.2. Upper gastrointestinal polyps and cancer
In FAP, duodenal adenomas are present in approximately 90% of patients, and a
specific staging system is used to classify its severity (Spigelman et al 1989).
Experimental data from mice indicate that unconjugated bile acids may promote
periampullary tumor formation (Mahmoud et al 1999). A small fraction of duodenal
adenomas follow the adenoma-carcinoma sequence with somatic alterations of APC and
K-ras genes (Gallinger et al 1995).
Hamartomatous gastric fundic gland polyps are relatively common, but they have low
malignant potential (Debinski et al 1995). Gastric adenomas are infrequent, but, when
present, may progress to gastric cancer, especially in geographic areas with a high
gastric cancer incidence (Park et al 1992).
4.1.3. Desmoids, osteomas, and dermal tumors
Desmoids are histologically benign, infiltrative, and non-metastasizing fibromatous
tumors that complicate FAP in about 10% of cases. Previous abdominal surgery,
estrogens, and female gender are associated with increased risk of desmoids. FAP-
related desmoids often grow intra-abdominally or within the abdominal wall and cause
severe morbidity because of ileic and urinary tract compression (Clark et al 1999). It23
has been argued whether desmoids result from reactive (polyclonal) or neoplastic
(monoclonal) growth. Both sporadic and FAP-related desmoids lack telomerase activity
(Scates et al 1998). However, an analysis of the polymorphic X-chromosomal CAG
microsatellite within the androgen receptor gene in desmoids from female FAP patients
suggests a neoplastic origin (Middleton et al 2000).
The most common osseus tumors associated with FAP are globoid osteomata of the
mandible and osteomatous changes in the calvaria. Sebaceous or epidermoid cysts,
especially in the back, are encountered in Gardner's syndrome (Phillips et al 1994).
4.1.4. Other FAP manifestations
When systematically screened for, congenital hypertrophic pigmentary lesions of the
retina (CHRPE) are found in about 60-80% of FAP patients. When multiple (>5) and
bilateral, they are considered as a pathognomonic sign of FAP and verify the diagnosis
in young children before the polyps develop. CHRPE lesions do not affect sight, neither
have they malignant potential. They are associated with APC mutations between codons
457 and 1444 (Olschwang et al 1993).
Hepatoblastoma is a rare tumor affecting small children and infants. Its incidence is
1/100 000 in the general population, but it occurs in 0.5% of FAP patients (Hughes and
Michels 1992). Somatic alterations of APC and β -catenin are common in sporadic
hepatoblastomas (Oda et al 1996, Koch et al 1999).
The thyroid cancer affects 1.2 % of FAP patients (Bülow et al 1997). Over 90% of
cases occur in females and show multifocal papillary differentiation. Somatic loss of
APC function associated with gain-of-function mutations in RET/PTC-1 and RET/PTC-
3 are found in both sporadic and FAP-associated papillary thyroid carcinomas (Cetta et
al 1998, Soravia et al 1999).
The prevalence of incidental adrenal adenomas was 7.4 % among FAP patients
compared with 0.6-3.4 % reported in general populations (Marchesa et al 1997).
Occasional secreting adenomas and malignant carcinomas have been reported.
4.2. Molecular genetic background of FAP
4.2.1. APC protein function
The large APC protein interacts with several cytoplasmic proteins (see Figure 4). APC
is functional as a homodimeric complex, and the very N-terminus is needed for
dimerization. This region remains intact in most truncated proteins, suggesting a
dominant negative effect on wild type APC (Su et al 1993). The APC region between
codons 453 and 767 has a high degree of homology with a similar area in β -catenin and
with its Drosophila homolog armadillo. This region binds with the regulatory B56
subunit of the PPA2 protein that binds with the AXIN and ASEF proteins (Seeling et al
1999, Kawasaki et al 2000).
Three 15- and seven 20-amino-acid repeats in the middle part of APC bind with β -
catenin (Rubinfeld et al 1993), linking APC with cell adhesion and WNT signaling.
Binding of β -catenin at 20-amino-acid repeats occurs only after its phosphorylation by25
centrosomes (Tirnauer et al 2000). Lack of the most C-terminal part of the Apc protein
contributes to chromosomal instability (Fodde et al 2001).
4.2.2 Genotype-phenotype correlations in FAP
Phenotype variation between and within FAP families is wide. Although mutations in
specific parts of the APC gene correlate with some phenotypic features (see Figure 4),
the phenotypes of individual patients or families do not predict the site of the
predisposing mutation, nor can the mutation data determine decisions about appropriate
surgical methods (Friedl et al 2001).
Truncating mutations in the APC region between codons 1280-1500, comprising the
mutational hotspot codon 1309, are associated with severe disease (Nagase et al 1992,
Gayther et al 1994). The majority of somatic mutations in sporadic and FAP colorectal
tumors occur in this “mutation cluster region” (MCR) (Miyoshi et al 1992, Miyaki et al
1994). In both sporadic and FAP-related colon tumors, the site of the first APC
mutation seems to modulate the mode of the “second hit”. If it resides between codons
1192 and 1392, LOH of the wild allele is strongly selected, whereas the first mutation
outside the above-mentioned region is associated with the truncating MCR mutation
(Lamlum et al 1999, Rowan et al 2000). A similar reciprocal relationship is observed in
FAP-related desmoids. Germline mutations 5’ to codon 1403 are associated with a
somatic mutation beyond that boundary, whereas germline mutations beyond codon
1450 favors LOH as the second hit (Lamlum et al 1999).
Attenuated polyposis (AAPC) is associated with truncating APC mutations upstream of
exon 5, in the alternatively spliced part of exon 9 (shaded in Figure 4) or in the 3’ end
of exon 15 (Spirio et al 1993, van der Luijt et al 1995, van der Luijt et al 1996).
Mutations at the 5' part disrupt the dimerization region and result in a reduced level of
functional APC homodimers. Mutations in the alternatively spliced region of exon 9
produce mRNA that codes for a functionally appropriate protein (Friedl et al 1996),
and, a second mutation is needed in some other part of the allele, in addition to wild
allele inactivation, to promote tumorigenesis (Su et al 2000a).
In about 20% of FAP families, no APC germline mutation is detected with current
techniques. In one study, the monoallelic mutation analysis (MAMA) method was used
to show that the majority of patients with the FAP phenotype, but without the truncating
APC mutation, present with reduced expression of one allele suggesting promoter
inactivation (Laken et al 1999). Although somatic mutations in other WNT pathway
genes are found in sporadic colorectal tumors, desmoids, and hepatoblastomas, no
linkage or mutational data of other predisposing loci have been published in FAP.26
5. SCREENING AND GENETIC TESTING
The parameters that predict an underlying MSH2 or MLH1 germline mutation are young
age at colon cancer diagnosis, a family history suggestive of dominant inheritance, and
endometrial cancer in first-degree relatives (Liu et al 1995, Wijnen et al 1998a,
Farrington et al 1998). In female patients, two primary cancers (colon and endometrial)
imply a high risk for HNPCC (Millar et al 1999, Charames et al 2000). Laboratory
screening for MSI and/or immunohistochemical staining of tumor samples with MSH2,
MLH1, and MSH6 antibodies are used as pre-screening methods for targeting mutation
analysis (de Leeuw 2000, Terdiman et al 2001). However, missense mutations or
promoter hypermethylation may confound the immunohistochemical results.
In HNPCC, full colonoscopies at 1- to 3-year intervals beginning at 25 years (or 5 years
younger than the earliest colon cancer in the family) and removal of all premalignant
lesions is recommended (Burke et al 1997) and documented to reduce morbity and
mortality (Järvinen et al 2000). To screen for endometrial cancer, annual gynecologic
examinations, combined with endometrial suction biopsy or transvaginal ultrasound is
recommended, beginning from the age of 25 to 35 years. There are no established
protocols on screening for ovarian and uroepithelial cancers (Burke et al 1997).
In FAP, regular endoscopic screening should be started in the early teens,
complemented later with gastroduodenoscopy surveillance. About 20% of FAP cases
that arise as de novo mutations are usually diagnosed in the symptomatic phase of the
disease (Phillips et al 1994).
When the predisposing mutation in an HNPCC or a FAP family is known, specific
genetic testing can be offered to individuals at risk. Genetic testing is possible only after
informed consent, preceded by genetic counseling, to ensure appropriate information
about the disease and the testing procedure and to avoid misinterpretation of the test
results (Giardiello et al 1997, Syngal et al 1999).27
AIMS OF THE STUDY
1) To screen verified or putative HNPCC families for germline mutations in the two
major HNPCC-associated genes MHS2 and MLH1. Such mutation data allow predictive
genetic testing and focused clinical surveillance for family members at 50% risk of
having inherited the predisposing mutation.
2) To study the age and origin of the two common MLH1 mutations enriched in
Finland. The common genetic ancestry forms an interesting basis for further molecular
genetic studies aimed at looking for low-penetrance genes that would explain the
phenotypic variance observed between and within HNPCC families.
3) To study the modifying effect of genes involved in the metabolism of environmental
agents on the clinical phenotype of HNPCC in families with a uniform predisposing
mismatch repair gene defect.
4) To compare, by immunohistochemistry, the expression of the MLH1, MSH2, and
MSH6 proteins in colorectal and endometrial tumors from patients with a germline
mutation in either MLH1 or MSH2 in order to study the somatic role of these genes as
determinants of the tumor spectrum in HNPCC.
5) To study the genetic defects in the germline of Finnish FAP families, so as to lay the
ground for predictive molecular testing, studies on phenotype-genotype correlation, and
further molecular studies on possible phenotype modifiers.28
MATERIALS AND METHODS
Pedigree information, clinical data, and blood samples (Studies I-V)
Pedigree information about HNPCC and FAP families was retrieved from the Finnish
HNPCC Registry and the Finnish Polyposis Registry managed by Dr. Jukka-Pekka
Mecklin and Dr. Heikki Järvinen, respectively. When necessary, cancer diagnoses were
verified from the Finnish Cancer Registry. Blood samples for DNA and/or RNA
extractions were obtained from patients after voluntary consent. Anonymous blood
donor samples from the area with the highest incidence of HNPCC were collected in
collaboration with the Finnish Red Cross Blood Service and used as controls (Studies II
and V).
Tumor samples (Study IV)
Endometrial cancer patients with a known germline mutation in either MLH1 or MSH2
were identified, using the HNPCC Registry and the Finnish Cancer Registry. Paraffin-
embedded tissue samples from 42 gynecologic cancers were obtained from hospital
archives, and 35 colon cancer samples from close relatives were used as controls. Sliced
tissue material cut off from the blocks was used for DNA extraction, and microscope
slides were prepared for immunohistochemical analyses.
DNA and RNA extraction (Studies I-V)
DNA was extracted from white blood cells, cultured lymphocytes, or normal colonic
mucosa using either the proteinase K/phenol extraction method (Kunkel et al 1977) or
the salting-out method (Lahiri and Nurnberger 1991). The tissue material in paraffin
blocks was deparaffinized with xylene before DNA extraction. The guanidium
thiocyanate method (Chomczynski and Sacchi 1987) was used for RNA extraction from
cultivated lymphoblasts.
The making of cDNA (Studies I and III)
To produce cDNA, 1 µg of template RNA was used for a 20-µl reaction volume.
Standard amplification buffer (1.5 mM MgCl2), dNTP, random hexamere (Pharmacia
Biotech), RNase inhibitor (Promega) and 200 U of M-MLV/BRL reverse transcriptase
enzyme (Promega) were added, and the reaction mixture was incubated at 40°C for 90
min.
Mutation analyses (Studies I, V)
Denaturing gradient gel electrophoresis (Study I)
The two-dimensional DGGE protocol described by Wu et al (1996) was used to screen
mutations and polymorphisms in both the MLH1 and the MSH2 genes. The primers,
amplification conditions, and exon combinations used in the multiplex reactions are
described in the original article. After amplification, the PCR products were denatured29
at 96°C for 10 min, renatured for 1h at the respective annealing temperature to allow
heteroduplex formation, and subjected to electrophoresis in 9% polyacrylamide (PAA)
gel. The bands were visualized with ethidium bromide and UV light. The region
containing fragments of 100-500 bp was cut off and applied to another 9% PAA gel
with a 0-10% glycerol gradient for a second electrophoresis run. Samples showing
aberrant band patterns were re-amplified from genomic DNA and sequenced manually
(Murray 1989).
Heteroduplex analysis (Study V)
Exons 1-14 of the APC gene were screened with heteroduplex analysis to complement
the RNA-based protein truncation test. All exons were amplified separately using
previously published primers (Groden et al 1991). The primers covered the intron-exon
boundaries except for the splice acceptor sites of exons 1, 3 and 4. After amplification,
the samples were denatured at 95°C for 3 min and cooled to room temperature for 20-
30 min to allow heteroduplex formation. Then 5 µl of each PCR product was loaded on
to MDE gel (AT Biochem, USA) and run with 0.8 kV for 11-15 h at room temperature.
The gels were silver-stained. Samples showing aberrant bands were re-amplified from
genomic DNA and sequenced.
Protein truncation test (Study V)
Exon 15 of the APC gene was amplified from genomic DNA in four overlapping
fragments (numbered 2-5) as described by Powell et al (1993), and exons 1-8 (1A) and
7-14 (1B) were amplified from cDNA. The PCR was performed as for PCR-RFLP,
except that the “hot start” protocol was used to reduce unspecific amplification. The
annealing temperatures were 55°C for fragments 2,3 and 5, 63°C for fragments 4 and
1B, and 65°C for fragment 1A. Then, 4 µl of the PCR product was translated to protein,
using the TNT
® kit according to the manufacturer’s instructions (Promega). The protein
products were loaded on SDS-polyacrylamide gels (Novex
®) and electrophoresed for 4
h. The gels were dried and exposed to x-ray films over 1-3 nights at -70°C. Samples
showing the truncated protein were sequenced from the genomic DNA to determine the
underlying mutation.
Automated sequencing (Study V)
To sequence the respective genomic areas in samples that showed aberrant protein in
PTT, primer pairs that amplified 300-600 bp overlapping fragments were designed.
Samples with aberrant protein in fragments 1A or 1B were sequenced using the same
primers as in the heteroduplex analysis. The PCR products were purified with the
QIAquick purification kit (Qiagen) and used as templates for ABI PRISM Terminator
or ABI PRISM dRhodamine cycle sequencing kit reactions (Perkin-Elmer). The
sequence reaction products were electrophoresed and analyzed on Applied Biosystems
373 or 377 sequencers (Perkin Elmer). Sequencing was performed in both directions
and repeated at least once to verify the mutation.
Southern blotting (Study V)
Southern blot hybridization was used to search for large deletions or rearrangements in
the APC region in those families in which no truncative mutation could be detected.30
Genomic DNA (8 µg) was digested with BamHI, EcoRI, HindIII and KpnI enzymes
(New England Biolabs) and electrophoresed in 0.8% agarose gels (Bio-Rad
Laboratories) with 40V for 16 h. After ethidium bromide staining, UV illumination, and
photographic documentation of the gels, blotting onto Zeta-Probe GT membranes (Bio-
Rad) was done overnight. PCR fragments 1A, 1B, 2, and 5, labeled with (α−
32P)dCTP
using Klenow enzyme oligolabeling kit (Amersham Pharmacia Biotech), and purified
on Sephadex
® columns, were used as hybridization probes. Hybridization was carried
out at +65°C overnight, and the membranes were washed and exposed to x-ray films at
-70°C.
Microsatellite analysis (Studies II and V)
Fifteen polymorphic microsatellite markers spanning 19 cM around MLH1 were used to
construct the haplotypes in families with shared mutations 1 and 2 (Study II). Four
markers spanning 7 cM around APC were used to construct putative haplotypes in FAP
families (Study V). PCR amplification with (α -
32P)dCTP was performed as described
by Peltomäki and colleagues (1993b).
RH mapping (Study II)
The Stanford G3 radiation hybrid panel (http://www-shgc.stanford.edu) with a
resolution capacity of 0.5 cM was used in Study II to estimate the physical distance
between closely linked microsatellite markers. Panel DNA was amplified with all 19
MLH1 flanking microsatellite markers, and the RHMAP program (version 2.01) was
used to analyze the data.
Allelic-specific oligohybridization (Study V)
To screen the prevalence of APC E1317Q missense variant in 50 healthy chromosomes
(Study V), 10 µl of the respective PCR product was diluted in 3 x SSC and attached to
two separate Zeta-Probe GT membranes (Bio-Rad) using the Slot-blot device (Hoefer
Scientific Instruments). Twenty-mere probes designed to hybridize with either the
normal or the mutated allele were end-labeled with (γ -
32P)dATP (Amersham), using T4-
polynucleotide kinase (New England Biolabs). The filters were hybridized overnight at
65°C, washed and exposed to x-ray films.
PCR-RFLP analysis (Study III)
PCR was performed using 150 ng of template DNA or cDNA in 50-µl reaction volume.
The PCR mixture contained 1x standard buffer (1.5 mM MgCl2), 200 µM dNTP
(Finnzymes), 1 µM of each primer, and 0.5 U of AmpliTaq DNA polymerase (Perkin
Elmer). After initial denaturation at 94-95°C for 4 min, 30 cycles were performed as
follows: denaturation for 1 min at 95°C, 30-60 sec at annealing temperature, and
extension for 1 min at 72°C, followed by final extension at 72°C for 8-10 min.31
Restriction fragment length polymorphisms (RFLP) were used to genotype the NAT1
and GSTM1 alleles, as described in Study III. The PCR fragments were digested with
the respective enzymes (MboII, New England Biolabs, HaeII, Promega) and separated
according to size using 4% Nusieve
® agarose gels. After electrophoresis, the gels were
stained with ethidium bromide and examined under UV light.
Immunohistochemistry (Study IV)
To study the expression of the MLH1, MSH2, and MSH6 proteins in the endometrial
and colon cancer samples from HNPCC patients who were known to be carriers of a
germline mutation in either MLH1 or MSH2, full length mouse monoclonal antibodies
against MLH1 (13271A; PharMingen) and MSH6 (2D4; Serotec), as well as mouse
monoclonal antibody recognizing the aminoterminal part of MSH2 (NA26;
Calbiochem) were used. Immunohistochemical staining was performed as described in
Kuismanen et al (1999).
Statistical methods (Studies III-V)
Fisher's exact test (with the Bonferroni correction in Study III), the χ
2 test and Student's
t test were used to estimate the statistical significance of genotype-phenotype
associations. The SIMIBD program (Davis et al 1996) was used to analyze the
segregation of colon tumor location with NAT1 and GSTT1 genotypes (Study III).32
RESULTS
MLH1 AND MSH2 MUTATIONS IN FINNISH HNPCC FAMILIES (Study I)
Germline mutations in MLH1 and MSH2 were studied in representatives of 55 Finnish
HNPCC families from whom blood samples were available. Thirty-five of the families
fulfilled the Amsterdam criteria I that were applied at the time of the study. First, RT-
PCR was used to look for truncating mRNA transcripts. In cases with no truncated PCR
product, both genes were amplified from genomic DNA in single exon or multiplex
reactions as described in the article, and analyzed with both the conventional DGGE
and the novel two-dimensional application (Wu et al 1996). The latter method proved to
be more efficient, and was later applied also in the search for somatic and germline
mutations in a series of MSI-positive sporadic colorectal tumors (Wu et al 1997).
Twenty-six families (26 of 55, 47%) carried one or other of the two Finnish founder
mutations (Nyström-Lahti et al 1995). Three families shared the same MLH1 missense
mutation (I107R), while the remaining mutations were unique (two in MSH2, and three
in MLH1, see Table 1). The RT-PCR analysis revealed deletions of exon 12 of the
MLH1 gene in two families, but, because precise data on the intron-exon boundaries
were not available at the time when the study was done, the genomic basis of these
deletions could not be characterized and the underlying splicing defects were identified
in a later study (Holmberg et al 1997).
Altogether, 130 verified or putative HNPCC families have been reported to the Finnish
HNPCC registry, and the 15 different published MLH1, MSH2, and MSH6 mutations
account for 78 families (78/130 = 60%), as summarized in Table 1. The high proportion
of two (75%) or three (85%) common founder mutations is a unique feature compared
to any other population reported in the literature. Germline mutations in other mismatch
repair genes (PMSI, PMS2, MSH6, or MSH3) are rare in families that screened negative
for MLH1 or MSH2 mutations (Huang et al 2001), which may indicate some other, as
yet unrevealed, genetic background.33
Table 1. Germline mutations in Finnish HNPCC families. The numbers in parentheses
in the first column indicate the numbers of families sharing the same mutation. Families
with mutations indicated with an asterisk (*) in the second column were included in
Study IV.
Gene Nucleotide change Protein change Reference
MLH1 (42) Exon 16, 3.5 kb genomic
deletion (Mutation 1)*
In-frame deletion
of exon 16
1)
MLH1 (14) IVS6 –1 g => a (SA)
(Mutation 2)*
Out-of-frame deletion
of exon 6
1)
MLH1 (7) Exon 4, n320 T => G*
(Mutation 3)
Ile107Arg 2)
MLH1 (2) Exon 17, n1975 C => T* Arg659stop 2)
MLH1 (2) Exon 17, n1976 G => C* Arg659Pro 2)
MLH1 (1) IVS14-1 g => t (SA)* Out-of-frame deletion
of exon 14
2)
MLH1 (1) IVS12-1 g => a (SA)* Out-of-frame deletion
of exon 12
3)
MLH1 (1) IVS12+1 g => c (SD)* Out-of-frame deletion
of exon 12
3)
MLH1 (1) IVS14-2 a => c (SA) Out-of-frame deletion
of exon 14
3)
MLH1 (1) Exons 3 - 5,
genomic deletion
In-frame deletion
of exons 3-5
3)
MLH1 (1) Exon 4, n378 C => G Tyr126stop 5)
MSH2 (2) Exon 10, n1550 delCA* Frameshift 2)
MSH2 (1) Exon 12,
n1860-1861 insTG
Frameshift 2)
MSH2 (1) IVS9-1 g  => t (SA) Splicing defect 4)
MSH6 (1) Exon 4, n3052 delCT Frameshift 6)
References: 1) Nyström-Lahti et al 1995, 2) Nyström-Lahti et al 1996, 3) Holmberg et al 1997,
4) Wu et al 1997, 5) Salovaara et al 2000, 6) Huang et al 200134
AGE AND ORIGIN OF TWO COMMON MLH1 MUTATIONS (Study II)
The demographic history of Finland is well documented, and so affords an excellent
basis for medical and molecular genetic studies (Peltonen et al 1995, de la Chapelle and
Wright 1998). Blood samples from 19 families sharing mutation 1 and from six families
sharing mutation 2 were available for the study. We addressed the questions “when and
where were the two common MLH1 mutations introduced into the Finnish population”
by constructing haplotypes that spanned 19 cM around the MLH1 gene. We
implemented the formula Q = [1-(1-θ )
g](1-pN) originally used by Risch et al (1995) to
estimate the age of the DYT1 founder mutation that causes dominantly inherited
idiopathic dystonia (OMIM 128100) in Ashkenazi Jews.
Only one (D3S1611) of the 15 dinucleotide markers used is intragenic, now known to
be located at IVS12 (http://www.nfdht.nl). Because we failed to find new intragenic
microsatellite markers, we designed as dense a map as possible, using highly
polymorphic flanking markers, with the aim of detecting all the possible recombinations
within the MLH1 region. Some markers were so closely linked that no meiotic
recombinations between them had been observed among eight large CEPH families
(http://www.cephb.fr). We therefore used the Stanford G3 radiation hybrid panel, which
has a resolution capacity of approximately 0.5 cM, to determine the relative location of
closely linked markers. However, the estimates of the physical distances between
markers obtained with this panel were 2-20 fold larger than the estimated distances in
the CEPH database. Thus, in our “age” calculations we relied on the latter values
whenever possible.
The linkage disequilibrium approach has been successfully used to map the genes
underlying many recessive diseases of the “Finnish disease inheritage” with both old
and relatively young founder mutations (Hästbacka et al 1994, Höglund et al 1995). In
addition to the above-mentioned formula designed for another population, we assessed
the degree of linkage disequilibrium using equation pexcess = (pD - pN)/(1-pN), where pD is
the frequency of the associated alleles on disease chromosomes and pN is the frequency
of the same allele on normal chromosomes. pN values were obtained from 50 normal
chromosomes representing either noncarriers from our HNPCC families or anonymous
blood donors from the geographical area with highest HNPCC incidence (see Figure 2
in Study II).
According our calculations, the expansion of mutations 1 and 2 began 16-43 (or 15-27)
and 5-21 (or 9-24) generations ago, respectively. Both estimates have wide support
intervals. Interestingly, two families with mutation 1, who share a substantially shorter
haplotype, originated near the eastern border of Finland. We assume that these families
represent the haplotype that is closer to the original. This observation, and knowledge
about the historical population movements in the respective geographic areas (see
Figure 2 in Study II), suggests that mutation 1 (and possibly mutation 2) were
introduced from the East. To our knowledge, neither mutation has been reported outside
Finland (http://www.nfdht.nl)35
ASSOCIATION BETWEEN POLYMORPHISMS IN GENES CODING FOR
CARCINOGEN-METABOLIZING ENZYMES AND SOME CLINICAL
PARAMETERS IN HNPCC (Study III)
We took advantage of the uniform genetic predisposition of the Finnish HNPCC
families to analyze the association between the putative GSTM1, GSTT1, and NAT1 risk
alleles and some clinical parameters related to colon cancer (age at diagnosis and tumor
location) that might reflect the role of these polymorphic enzymes in colon
carcinogenesis.
DNA extracted from blood leukocytes was available from 78 Finnish patients with
HNPCC sharing mutation 1, and from 14 patients sharing mutation 2. Their NAT1
alleles *3, *4, *10 and *11, GSTM1 alleles A, B, and null, and GSTT1 null genotypes
were determined. As we reasoned that the first colectomy would bias the site of
metachronous cancers, only the first colorectal cancer of each patient was included in
the analysis. The proportion of proximal and distal cancers in the whole series (59 vs.
33, or 1.8) was typical for HNPCC.
Among mutation carriers and non-carriers from the same families, the frequencies of
the NAT1, GSTM1, and GSTT1 alleles did not differ, and were comparable to the
frequencies reported in the literature for Caucasian populations (Bell et al 1995a,
Rebbeck et al 1997). This was to be expected, since none of the genes is linked to
MLH1. There are relatively more extracolonic cancers (especially endometrial cancers)
in relation to colorectal cancers among mutation 2 carriers than among mutation 1
carriers (Peltomäki et al 2001). The basis for this difference in phenotype is not known.
On account of the small number of colon cancer patients with mutation 2 (n = 14), no
statistically significant associations could be obtained in this group.
In the mutation 1 group, the presence of the NAT1*10 allele, assumed to cause a “rapid
acetylator” phenotype because of prolonged mRNA degradation (Bell et al 1995b), was
associated with distal tumor location and with a somewhat earlier age at the first colon
cancer diagnosis. We tried to confirm this finding with the SIMIBD simulation program
(Davis et al 1996), but there were too many missing links in the respective pedigrees.36
DIFFERENT EXPRESSION OF MSH2 AND/OR MSH6 IN ENDOMETRIAL
AND COLON TUMORS IN PATIENTS HARBORING GERMLINE
MUTATION IN MLH1 OR MSH2 (Study IV)
Paraffin-embedded colon and endometrial tumor samples from patients with a known
mutation in either the MLH1 or the MSH2 gene were collected as part of a project that
aims to study molecular determinants of phenotype variance among Finnish HNPCC
families. As the first step in this project, we analyzed the expression patterns of the
MLH1, MSH2, and MSH6 proteins, using immunohistochemical staining. A parallel
study concentrating on MSI, MLH1 promoter methylation status, and LOH at the MLH1
and MSH2 loci in the same tumor material has been carried out and will be published
separately (Kuismanen et al, manuscript submitted).
Our family material comprises a strong predominance of MLH1 germline mutations. As
expected from the "two-hit" hypothesis, all the tumors from the MLH1  mutation
carriers, whether colorectal or endometrial, lacked nuclear expression of the MLH1
protein in the tumor cells. Analogously, lack of MSH2 expression was found in all eight
tumors from individuals with the germline MSH2 mutation. Interestingly, about 50% of
the endometrial tumors but none of the colorectal tumors of the MLH1  germline
mutation carriers lacked either MSH2 or MSH6 expression either partly or totally. In all
cases, normal non-tumor tissue showed strong nuclear staining, suggesting that
inactivation of MSH2 and/or MSH6 had occurred during tumorigenesis.
Our results are in good accord with the observations that MSH6 germline mutations
strongly predispose to the endometrial cancer phenotype, emphasizing the prominent
role of the inactivated MutSα  complex in the pathogenesis of HNPCC-related
endometrial cancer. Moreover, detailed MSI analysis indicated a milder MSI phenotype
in endometrial tumors than in colon tumors, further highlighting the tissue-specific
differences in tumors with similar predisposing MLH1 or MSH2 mutations (Kuismanen
et al, manuscript submitted).37
GENETIC AND CLINICAL ANALYSIS OF FINNISH FAP FAMILIES (Study
V)
Germline APC mutations have not previously been characterized among Finnish
families with familial adenomatous polyposis. We conducted a population-based study
of 65 FAP families in which at least one affected individual had been found, at
diagnosis, to have 100 or more colon polyps. We aimed to determine the predisposing
APC mutations, and to lay a foundation for the molecular genetic testing facility at the
Helsinki University Central Hospital. Genotype-phenotype correlations, using the
available clinical data, were also performed.
PTT and heteroduplex analysis were used to screen for truncating mutations along the
large APC gene (see Materials and Methods). Altogether, 38 different mutations in 47
of the 65 FAP families studied (72%) were detected. Most of the mutations were unique
to each family, in strong contrast with the situation in the Finnish HNPCC families. Six
mutations, including the 5 bp deletion at codon 1309, were shared by two to four
families. Genotyping with four microsatellite markers indicated that there was only one
case (a 5 bp deletion at codon 1059 shared by three families) in which a putative
common haplotype could be constructed. Our genotyping data did not suggest any
evidence for a founder effect among those FAP families, in whom we did not detect
truncating APC mutations.
Interestingly, the E1317Q variant was found in one Finnish FAP family whose
members presented with classical polyposis, relatively late age at diagnosis, and a high
risk for malignancy. Because a blood sample was available from only one affected
individual in whom no other APC mutation was found, we could not test the co-
segregation of this variant with the FAP phenotype, and this family was included in the
“mutation not found” group in the genotype-phenotype analysis. The E1317Q variant
was not found among 50 control chromosomes representing anonymous blood donors.
Since this study was completed, gene sequencing has revealed an APC mutations in two
families in which the cell line culture failed, and no RNA-based mutation screening
could be done. Both mutations reside in the APC region that was not properly covered
by PTT from only genomic DNA (Irma Järvelä, personal communication).
The genotype-phenotype correlations found among Finnish families were in good
concordance with the previous literature. Desmoid tumors were significantly more
common among the patients with a truncating mutation beyond codon 1403. No
correlation was observed between the site of the mutation and the presence of duodenal
adenomas. Interestingly, we observed a higher mean age at polyposis diagnosis in the
group of families with no identifiable APC mutation. Exclusion of the two above-
mentioned families from the “mutation not found” group further increases this
difference (data not shown). Since large genomic rearrangements in the APC region
were excluded by Southern blot analysis, and no evidence of reduced allele expression
was observed, this finding leaves the door open for the identification of other
predisposing loci in FAP.38
COMPARISON OF GENETIC PREDISPOSITION TO HNPCC AND TO FAP
IN FINNISH FAMILIES
The essential characteristics of hereditary predisposition to one or the other of the two
syndromes are compared in Table 2.
Table 2. The numbers of Finnish HNPCC and FAP families screened for predisposing
mutations, the methods used, and the types of germline changes observed. The numbers
in parentheses indicate the changes observed in each mutation category.
HNPCC FAP
Number of families
studied
55 65
Genes analyzed MLH1, MSH2 APC
Screening methods DGGE, RT-PCR PTT, heteroduplex analysis,
Southern blot
Mutation detection rate 65% 72%
Types of pathogenic
mutations
Large genomic deletion (1)
Splice site mutations (2)
Deletions/insertions (2)
Nonsense (2)
Missense (2)
Splice site mutations (2)
Deletions/insertions (20)
Nonsense (16)
Nonpathogenic variants Silent (1)
Missense (2)
Intronic (2)
Missense (1)
Types of mutations that
might escape detection by
the present methods
Large genomic deletions/
rearrangements
Regulatory changes
Large genomic deletions/
rearrangements
Regulatory changes
De novo mutations 0/55 (0%) up to 15/65 (23%)
Founder effect Yes No39
DISCUSSION
This study characterizes the spectrum of predisposing mutations in Finnish HNPCC and
FAP families. Since no single mutation detection technique can detect all possible
genetic variants, several methods were used to screen for the predisposing germline
mutations in the MSH2, MLH1 and APC genes. The short coding exons were screened
from genomic DNA using DGGE or heteroduplex analysis, where the shift in the gel
electrophoresis mobility identifies the mutant variant from the wild type allele. The
RNA-based RT-PCR and PTT are relatively easy and rapid methods to screen for splice
site defects or coding truncating mutations that lead to shorter transcripts because of
exon skipping or premature stop, respectively. The Southern blot was used without
success to look for large genomic deletions that are known to account for a substantial
portion of families, in which the predisposing mutation escape the PCR-based methods
(Nyström-Lahti et al 1995, Wijnen et al 1998b, Su et al 2000b). The rapid development
in the field of mutation detection methods, such as the new conversion technology (Yan
et al 2000), gives hope that the underlying genetic defect in part of the mutation-
negative families may be identified in the future.
The population genetics in Finland was found to differ between the two hereditary
colorectal cancer syndromes. In HNPCC, two or three common MLH1 mutations
account for 75% or 85% of the mutation-positive families, respectively (see Table 1). In
addition, we were able to show that the estimated time since the start of expansion of
the two MLH1 founder mutations correlates with our knowledge about population
movements within this country. Conversely, estimates of the age of particular alleles
could be used in reconstruction of demographic processes and population histories
(Slatkin and Rannala, 2000)
Our work has laid a solid basis for further mutation studies in Finnish HNPCC families,
and the specific tests developed for mutations 1 and 2 (Nyström-Lahti et al 1995) are
being widely applied both in clinical diagnostic work and in scientific research. At the
present time, screening for the three common founder mutations is sufficient to
determine the causative HNPCC mutation with 80% probability. For comparison, the
BRCA1 and BRCA2 genes account for about 30% of hereditary breast and/or ovarian
cancer in most populations (Szabo and King 1997). In Finland, germline mutations in
BRCA1 or BRCA2 are found in 20% of the families with three or more affected first- or
second-degree relatives (Vehmanen et al 1997), and 11 recurrent mutations cover more
than 80% of these mutation-positive Finnish families (Sarantaus et al 2000). In contrast,
no significant founder effect was found among Finnish FAP families, and most of the
mutations seem unique to each family.
Mouse models have been created for studies of pathogenic mechanisms in mammalian
settings. Both mice knock-out of mismatch repair genes (de Wind 1995, Prolla et al
1998), and mice harboring mutations in different parts of the murine Apc gene (Su et al
1992, Smits et al 1998) are valuable tools for these studies. However, many problems
relating to the human phenotype variation have not been resolved properly. Large
families (Scott et al 1995), and widely distributed or recurrent mutations, such as the
Finnish mutations 1 and 2, or the MSH2 mutation at the 3’ splice site of exon 5 which is
common among HNPCC families in England, Newfoundland, and the United States
(Froggatt et al 1999), provide useful tools for detailed genotype-phenotype analyses.40
The difficulty of determining clear genotype-phenotype correlations in HNPCC
emphasizes the role played by modifier genes and environmental factors in explaining
the variation in clinical phenotypes. In FAP, genotype-phenotype correlation studies
conducted to date have mostly focused on detailed analyses of the effect of the site of
the APC mutation in colon tumorigenesis. The precise role of the APC protein in
extraintestinal manifestations of FAP, many of which are derived from mesenchymal
cells, has not been elucidated.
In addition to this study, other investigators have linked HNPCC phenotype parameters
with low penetrance candidate genes. Among Swiss MLH1/MSH2 mutation carriers,
there were significantly fewer unaffected individuals in the group with the slow NAT2
acetylator allele (NAT2*4) as compared with the rapid acetylator alleless (Heinimann et
al 1999). Futhermore, the 1853N variant of the ATM D1853D polymorphism was
associated with increased incidence of both colon cancer and extracolonic cancer
(Maillet et al 2000). A common cyclin D1 polymorphism (A870G) postulated to
increase alternative RNA splicing was shown to be associated with earlier onset of
cancer in North American HNPCC families (Kong et al 2000), while, among Finnish
families, an early onset is associated with the presence of the alternatively spliced
mRNA variant in blood leukocytes, but not with A870G polymorphism (Bala and
Peltomäki 2001). In a large Swiss FAP family with a truncating APC mutation at codon
1982, extracolonic manifestations may be associated with the slow NAT2 acetylation
genotype (Scott et al 1997), but not with COX-2 polymorphisms (Humar et al 2000).
We cannot exclude the possibility that our results are biased, because in MLH1
mutation carriers with NAT1*10, some other closely linked polymorphic gene(s), such
as NAT2 (Smelt et al 1998), may contribute to the predilection of distal tumor location.
Moreover, the RFLP method we used does not differentiate between the “rapid”
NAT1*10  and the “slow” NAT1*14, which was discovered after our study was
conducted (Payton and Sim 1998). The frequencies of NAT1 alleles vary between
populations (Hein et al 2000), and, although the frequency of NAT1*14 is unusually
high among the Lebanese (Dhaini and Levy 2000), data of its prevalence in Caucasian
populations are not available.
Comparison between colorectal and endometrial HNPCC tumors from patients with
similar predisposing germline mutations in MSH2 or MLH1 revealed differences in the
expression of MutSα  proteins, although this study did not aim to analyze the exact
inactivation mechanism of MSH2 and/or MSH6. The MutSα  proteins are known to be
unstable in the absence of either partner, as is also evident from our observation that
MSH6 expression was absent in most tumors from carriers of the MSH2 germline
mutation. However, the mechanism underlying the specific lack of MutSα  protein
expression in endometrial, but not in colorectal, cancers in carriers of the MLH1
mutation warrants further study. Recently, the coding (A)7 tract of MSH2 was found to
be somatically mutated in two sporadic endometrial cancers with the MSI phenotype
(Chadwick et al 2001), and previously the (C)8 tract of MSH6 was shown to be a
common target for MSI in endometrial cancers (Wijnen et al 1999). Even though the
actual mechanism remains unknown, inactivation of MutSα  is probably a primary, and
not a secondary, event in HNPCC-related endometrial carcinogenesis.41
CONCLUSION AND FUTURE PROSPECTS
This thesis consists of molecular genetic studies on two dominantly inherited
syndromes, HNPCC and FAP, predisposing to colorectal cancer. The two syndromes
have different genetic backgrounds, a different molecular pathogenesis, and different
treatment guidelines. Nevertheless, they have much in common. Patients and family
members who are at 50% risk of having inherited the predisposing gene allele need
regular colonoscopic screening and prophylactic surgery to prevent a malignant
outcome. They need genetic counseling and psychologic support. Molecular geneticists
have added mutation detection and predictive testing facilities to routine clinical
practice.
Germline mutations in at least three genes (MLH1, MSH2, and MSH6) occur in
HNPCC, but in about 30-40% of the families with clinically verified HNPCC the
predisposing mutation cannot be identified with the screening methods currently used.
In FAP, identification of the predisposing APC mutation fails in about 20% of families
in most studies, including ours. A genome wide search for linkage is in progress among
Finnish mutation-negative HNPCC families. Studies of germline mutations in candidate
genes to find new predisposing loci in FAP remain an interesting challenge.
A good understanding of the molecular background of phenotype variation in cancer
syndromes is important not only for academic science, but also for genetic counseling
purposes and for the designing of well-targeted screening and treatment
recommendations. Comparison of genetic and protein expression profiles in tumors
gives clues to tissue-specific pathogenic mechanisms. Preliminary simulation data
indicates that the series of Finnish HNPCC families sharing two MLH1  founder
mutations is large enough to pinpoint tumor-specific modifier genes with moderate
penetrance. In FAP, comparison of discordant sib pair in large collaborative setting has
been suggested as a possible approach for identifying phenotype modifiers (Houlston et
al 2001).
In the vast majority of cancer cases, the risk to family members is non-existent or
negligible. Identifying low-penetrance genes that contribute to the risk of sporadic
cancer at the general population level is a challenge for the future (Houlston and
Tomlinson 2001). The new technical achievements provide us with the possibility to
analyse thousands of single nucleotide polymorphisms (SNPs) in large series (Syvänen
2001). Although completion of the human genome project will increase the number of
candidate genes, and the rapid development of computerized screening methods will
augment the power of experimental research, the problem of how to control the
complex human genetic background and environmental exposure to carcinogens
remains a challenge. Repeated confirmatory studies are needed before any data on low-
penetrance polymorphisms can be used in genetic counseling or in life-style
recommendations for patients with a high risk of hereditary cancer.42
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